1
Return

Real-World Effectiveness and Safety of Recombinant Human Follicle-Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study

delete2025-12-02
delete0
delete
OA
AI
J
Joong Yeup Lee
E
Eun‐Young Choi
J
Jung Ryeol Lee
Y
Young Sik Choi
J
Ji Hyang Kim
C
Chang‐Woo Choo
Y
Yunju Choe
H
Hee‐Jin Seo
H
Hyesung Lee
Y
Yujeong Shin
Y
Ye Jin Jeon
J
Ju‐Young Shin *
H
Hoon Kim *
DOI:10.1002/cpt.70136delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Despite widespread rhFSH use in infertile women undergoing ART, real-world comparative data on its effectiveness and safety across different rhFSH types remain limited. Using the HIRA claims database, we included 10,684 women aged 20–39 with infertility (2016–2021) who used only rhFSH in their first in vitro fertilization–embryo transfer (IVF-ET). Outcome variables comprised effectiveness (≥ 11 oocytes retrieved, pregnancy rates and live birth rate) and safety (ectopic pregnancy, miscarriage, preterm birth and ovarian hyperstimulation syndrome [OHSS]) in the whole cohort, further categorized into follitropin and other rhFSH. Baseline characteristics were described, and relative risks (RR) with 95% confidence intervals (CI) were estimated using a generalized linear model, adjusting for age and imbalanced variables. Of 10,684 patients prescribed rhFSH, 7.1% were aged 20–29, 41.6% were 30–34, and 51.3% were 35–39. ICSI was utilized in 57.7% of cycles, and 76.8% used the GnRH antagonist protocol. The live birth rate was 38.8%, and the OHSS rate was 5.9%. Comparing baseline characteristics of the follitropin (n = 2,594) and other rhFSH group (n = 8,090), ICSI (62.2% vs. 56.3%) and GnRH antagonist protocol (81.3% vs. 75.3%) were more common in the follitropin group. Women who received follitropin were more likely to have ≥ 11 oocytes retrieved (adjusted RR, 1.09; 95% CI: 1.02–1.16) and less likely to have OHSS (adjusted RR, 0.73; 95% CI: 0.60–0.90). These findings provide real-world evidence supporting rhFSH effectiveness and safety in fresh IVF cycles, with follitropin potentially offering advantages in oocyte retrieval and reduced OHSS rates.
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

C
Clinical Pharmacology and Therapeutics
IF:
5.5
Papers:
8.6K
Citations:
1.9W

Organization

S
seoul maria fertility hospital
Scholars:
1
Papers: 1
Citations: 0
C
cha university bundang medical center
Scholars:
17
Papers: 6
Citations: 0
S
Seoul National University Bundang Hospital
Scholars:
584
Papers: 245
Citations: 5.6K
S
Sungkyunkwan University
Scholars:
2.8K
Papers: 1.1K
Citations: 2
S
seoul national university college of medicine
Scholars:
877
Papers: 325
Citations: 0
Y
Yonsei University College of Medicine
Scholars:
1.8K
Papers: 571
Citations: 1
H
hamchoon women’s clinic, seoul, south korea
Scholars:
1
Papers: 1
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers